Liraglutide and insulin have contrary effects on adipogenesis of human adipose-derived stem cells via Wnt pathway
Key Developments In April 2025, Meitheal Pharmaceuticals, Inc., announced that it received approval from the U.S
Small portions, protein first, plenty of water
For patients seeking sustainable weight loss, this shift has raised an important question: What happens when medication access changes or ends entirely
Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation
Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Amgen, Inc.